Janet Munro

Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom.

Perceptronix Medical, Inc. provides cytology laboratory and cancer diagnostics services. It provides partnership opportunities for the distribution and test sales of quantitative cytology imaging machine including ClearCyte. The firm also provides software and staining kit Clear2C. Its products are used in hospitals, universities and commercial laboratories. The company was founded in 1999 and is headquartered in Vancouver, Canada.

Babraham Bioscience Technologies Ltd. provides business research and consulting services. It also offers financial and administrative services to start-up biotech companies. The company was founded in 1996 and is located in Cambridge, UK

Mabey Holdings Ltd. provides steel fabrication services. Its services include bridging, engineering and project, and training and education. The company was founded in 1923 and is headquartered in Reading, the United Kingdom.

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

Part of Tripos, Inc., Receptor Research Ltd. provides drug discovery informatics products and services. The company is based in Bude, UK. Receptor Research was acquired by Tripos, Inc. on November 18, 1997.

The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Idameneo (No. 789) Ltd. provides diagnostic and wellness products and services. It offers services through its pathology, diagnostic imaging, medical centers, and pharmacy services divisions. The company is headquartered in St Leonards, Australia..

Oxford Capital Partners LLP (Oxford Capital Partners) is a venture capital subsidiary of Oxford Capital Partners Holdings Ltd founded in 1999 by Tedd Mott and David Edward Christian Mott. The firm is headquartered in Oxford, United Kingdom.

Biocleave Ltd. develops and sells microbial technology for the production of renewable chemicals and biofuels. It also provides biobutanol and other C4 chemical products. The firm also engages in microbiology and metabolic engineering through fermentation and commercial production scale. Its products include biobutanol chemicals and fuel, acetone, and butyric acid. The company was founded by Edward M. Green in 2003 and is headquartered in Abingdon, the United Kingdom.

Aitua Ltd. engages in the commercialization of intellectual properties of companies in the field of life sciences. It provides support to new bio-ventures by investing in the initial stage. The company was founded in June 2006 and is headquartered in Cambridge, the United Kingdom.

BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Veryant, Inc. provides powerful COBOL and Java technology solutions to enable organizations to quickly and safely extend current applications to meet new business needs and demands. The private company is based in Westchester, IL. The company's portable, robust solutions translate into cost-effective, future-proof computing. Veryant's ISCOBOL Evolve enables organizations to retain current COBOL investments while simultaneously offering a path forward to take advantage of the openness, portability, and power of the Java platform without retraining staff or rewriting code.

Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom.

Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.

Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom.

Part of hVIVO PLC, hVIVO Services Ltd. is a British company that specializes in full-service viral challenge studies. The company is based in London, UK. The company's services include challenge models and lab services. The company was founded in 1988 by John Sidney Oxford.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom.

Part of Ixico Plc, IXICO Technologies Ltd. is a British company that provides data analytics services to the biopharmaceutical industry. The company is based in London, UK and was founded in 2004.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.